checkAd
    Startseite > Aktien > Genmab > Nachrichten
    Genmab Aktie
    28,55
     
    USD
    +1,42 %
    +0,40 USD
    Letzter Kurs 20:18:29 Nasdaq
    28,54
     
    USD
    100 STK
    Geldkurs 20:18:42
    28,56
     
    USD
    400 STK
    Briefkurs 20:18:42
    ISIN: US3723032062 · WKN: A1WZYB · SYM: GMAB · Dänemark

    Neueste Nachrichten

    Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
    03.04.24 · Business Wire (engl.) · Genmab
    U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
    27.02.24 · Business Wire (engl.) · Genmab
    Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
    02.02.24 · Business Wire (engl.) · Pfizer
    TIVDAK Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
    09.01.24 · Business Wire (engl.) · Pfizer
    TIVDAK (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
    09.01.24 · Business Wire (engl.) · Pfizer
    New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
    09.12.23 · Business Wire (engl.) · Genmab
    Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY/TEPKINLY) for the Treatment of Relapsed/Refractory Follicular Lymphoma
    27.11.23 · Business Wire (engl.) · Genmab
    Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)
    02.11.23 · Business Wire (engl.) · Genmab
    TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
    22.10.23 · Business Wire (engl.) · Genmab
    TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
    22.10.23 · Business Wire (engl.) · Genmab
    Genmab Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
    25.09.23 · Business Wire (engl.) · Genmab
    EPKINLY (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    25.09.23 · Business Wire (engl.) · Genmab